FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.
|Slideshows|August 12, 2019
Relevant Patient Odors for Mental Status Examinations
Author(s)Jonathan R. Scarff, MD
Utilizing our senses-sight, hearing, AND smell-during the patient interview can provide a comprehensive exam and assist in assessment and treatment.
Advertisement
Advertisement
Related to this article
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Andrew A. Nierenberg, MD, explains how a learning health network helps clinicians measure outcomes and redesign bipolar disorder care together with patients.
Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The New, Impending Adult ADHD Guidelines
2
What Makes Us Human? The Role of Psychiatry and the Future DSM
3
Reimbursement and Resources: Preparing Clinics for Psilocybin Therapy
4
Two New MDD Approvals: 5-HT1A Agonism and Adjunctive Atypical Antipsychotics
5